Newsletter Tool

Today's Rundown

Trending Topic: Emerging Biopharma
Explore emerging biopharma news and information, including the life sciences companies developing new technology and driving innovation.

Featured Story

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

By Angus Liu

A monkeypox outbreak is emerging in several regions, and at least one European country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe or Jynneos in the U.S.

Anthem shareholders OK rebrand as Elevance Health

By Paige Minemyer

The name combines the concepts of "elevate" and "advance," Anthem said, to reflect its efforts to grow beyond being a health insurance company.

FDA clears NeuroMetrix’s wearable neuromodulator as first non-drug fibromyalgia treatment

By Andrea Park

With the FDA’s nod, Massachusetts-based NeuroMetrix plans to launch the wearable, prescription-only Quell system as a fibromyalgia treatment in the fourth quarter of this year.

Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development

By Max Bayer

Amgen and deCODE Genetics say the future of their partnership is in the clinic, touting the impact gene hunting has on drug development. The aspirations were relayed at deCODE's belated 25th-anniversary event.

Catalent throws down $175M on yet another manufacturing expansion

By Fraiser Kansteiner

Production powerhouse Catalent has unveiled yet another manufacturing expansion, this time at a massive oral medicines plant that already doubled in size back in 2015.

XACT's needle-guiding robot scores FDA clearance for ablation procedures

By Conor Hale

This includes image-guided operations to burn out or freeze clumps of tumor cells without the need for open surgery. The new green light adds to the robot’s already broad clearance for performing CT-guided percutaneous procedures.

Enanta sinks to multiyear low as phase 2b RSV trial flames out

By Nick Paul Taylor

Enanta Pharmaceuticals’ bid to treat low-risk respiratory syncytial virus (RSV) patients has gone off the rails. The failure of the phase 2b trial of N-protein inhibitor EDP-938 in the population sent Enanta’s stock to its lowest ebb since 2017 but failed to extinguish the biotech’s belief in the prospect in other settings.

Transcarent launching behavioral health offering

By Paige Minemyer

Transcarent is rolling out a behavioral health offering that aims to boost access to care, a major challenge for people with mental health needs.

After Big Pharma pulls back in Russia, Dr. Reddy's says business is booming

By Kevin Dunleavy

Generic drugmaker Dr. Reddy’s Laboratories says it plans to launch new products in Russia after its business there delivered a whopping 70% revenue increase.

Nanobiotix scales down R&D plan, freezes hiring to close gap between cash runway and phase 3 data

By Nick Paul Taylor

Nanobiotix has joined the ranks of biotechs that are trying to eke out their cash reserves. With its cash down to 70.6 million euros ($74 million) and its phase 3 solid tumor trial still two years away from interim data, the French biotech is enacting a suite of changes intended to save up to 15 million euros a year.

Brain-computer interface zooms ahead in helping paralysis patient drive again

By Andrea Park

Nearly a decade after a car accident left him paralyzed from the waist down, Florida resident German Aldana Zuniga got back behind the wheel—thanks to a microchip implanted in his brain.

HHS commits $300M to global accelerator targeting antibiotic-resistant bacteria

By Dave Muoio

HHS and partners' new funds will support CARB-X, the world's largest public-private accelerator supporting early-stage therapies and diagnostics for antibiotic-resistant infections.